Journal of Mazandaran University of Medical Sciences
مجله دانشگاه علوم پزشکی مازندران
J Mazandaran Univ Med Sci
Medical Sciences
http://jmums.mazums.ac.ir
1
admin
1735-9260
1735-9279
fa
jalali
1401
12
1
gregorian
2023
3
1
32
218
online
1
fulltext
fa
بررسی فراوانی نوروپاتی محیطی ناشی از شیمی درمانی در بیماران مبتلا به سرطان مراجعه کننده به بیمارستان امام خمینی (ره) ساری
Frequency of Chemotherapy-Induced Peripheral Neuropathy in Cancer Patients in Sari Imam Khomeini Hospital
هماتولوژی و آنکولوژی
Hematology and Oncology
پژوهشي-کامل
Research(Original)
<div style="text-align: right;"><span style="font-size:12pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:95%"><span style="direction:rtl"><span style="unicode-bidi:embed"><span new="" roman="" style="font-family:" times=""><span lang="FA" style="line-height:95%"><span b="" koodak="" style="font-family:"><span style="color:black"> </span></span></span></span></span></span></span></span></span></span><span style="font-size:12px;"><span style="line-height: 2;"><span style="direction: rtl;"><span style="unicode-bidi: embed;"><span new="" roman="" times=""><span lang="FA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">سابقه</span></span></span></span><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.1pt;"> و هدف:</span></span></span></span> <span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">نوروپاتی محیطی ناشی از شیمی درمانی(</span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">CIPN</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">) یک شرایط ناتوان</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="letter-spacing: -0.1pt;"></span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">کننده می</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="letter-spacing: -0.1pt;"></span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">باشد، که ممکن است</span></span></span></span> <span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">نیاز به کاهش یا قطع دوز شیمی درمانی داشته باشد. شناسایی روش</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="letter-spacing: -0.1pt;"></span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">های موثر در درمان </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">CIPN</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">، نیازمند تعیین میزان فراوانی </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">CIPN</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"> است. با توجه به نبود مطالعه جامعی در کشور، مطالعه حاضر با هدف بررسی فراوانی نوروپاتی محیطی ناشی از شیمی درمانی در بیماران مبتلا به سرطان مراجعه کننده به بیمارستان امام خمینی (ره) ساری انجام گرفت</span></span></span><span lang="FA"><span b="" koodak=""><span style="color: black;">.</span></span></span><span lang="FA"><span b="" zar=""><span style="color:#0e101a"></span></span></span></span></span></span><br>
<span style="direction: rtl;"><span style="unicode-bidi: embed;"><span new="" roman="" times=""><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">مواد و روش</span></span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;"></span></span></span></span><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">ها:</span></span></span></span> <span lang="AR-SA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">این مطالعه طولی روی بیماران مبتلا به سرطان دریافت کننده مشتقات </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">Thalidomide</span></span></span><span lang="AR-SA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">، آلکالوئیدهای وینکا، تاکسان، مهارکننده</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">های پروتئازوم، پلاتینوم</span></span><span style="color: black;"><span style="letter-spacing: -0.1pt;">ها و ناپایدارکننده</span></span><span style="color: black;"><span style="letter-spacing: -0.1pt;">های میکروتوبول مراجعه</span></span><span style="color: black;"><span style="letter-spacing: -0.1pt;">کننده به مرکز جامع سرطان بیمارستان امام خمینی ساری (سال 1401-1400) انجام شد. سنجش نوروتوکسیسیتی توسط پرسشنامه </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">EORTC QLQ-CIPN20</span></span></span> <span lang="AR-SA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.2pt;">قبل از شروع سیکل شیمی درمانی و 3 ماه بعد مورد بررسی قرار گرفت. از آزمون</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="letter-spacing: -0.2pt;"><span style="color: black;">های آماری منویتنی و </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.2pt;">T-test</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.2pt;"> و </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.2pt;">chi-square</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;"> در نرمافزار </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">SPSS</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;"> جهت آنالیز آماری استفاده شد.</span></span></span></span><span lang="FA"><span b="" zar=""><span style="color:black"></span></span></span></span></span></span><br>
<span style="direction: rtl;"><span style="unicode-bidi: embed;"><span new="" roman="" times=""><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.2pt;">یافته</span></span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.2pt;"></span></span></span></span><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.2pt;">ها:</span></span></span></span><span lang="FA"><span b="" zar=""> در این بازه زمانی 103 بیمار وارد مطالعه شدند.</span></span><span lang="AR-SA"><span b="" zar=""> 54 بیمار (52/4 درصد) کمتر از 55 سال و 49 بیمار (47/6 درصد) در محدوده سنی بالای 55 سال قرار داشتند. 49 نفر (47/6درصد) در پیگیری 3 ماهه دارای نوروپاتی ناشی از شیمی درمانی بودند. درصد </span></span><span lang="FA"><span b="" zar=""><span style="color: black;">فراوانی </span></span></span><span lang="AR-SA"><span b="" zar="">علایم در زنان بیشتر</span></span><span lang="FA"><span b="" zar="">مشاهده شد،</span></span><span lang="AR-SA"><span b="" zar=""> اما فاقد معنیداری بود(<span style="color: black;">0/110=</span></span></span><span dir="LTR"><span style="color: black;">P</span></span><span lang="AR-SA"><span b="" zar="">). همچنین میانگین شاخص توده بدنی در بیمارانی که تجربه نوروپاتی داشتند، بیشتر از بیماران بدون نوروپاتی بود.</span></span><span lang="FA"><span b="" zar=""><span style="color:black"></span></span></span></span></span></span><br>
<span style="direction: rtl;"><span style="unicode-bidi: embed;"><span new="" roman="" times=""><span lang="AR-SA"><span b="" koodak=""><span style="color: black;"><span style="letter-spacing: -0.2pt;">استنتاج:</span></span></span></span> <span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">در مطالعه حاضر</span></span></span></span> <span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">نزدیک به نیمی از بیماران دچار عارضه </span></span></span></span><span dir="LTR"><span style="color: black;"><span style="letter-spacing: -0.1pt;">CIPN</span></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;"> شدند که نیاز به آموزش و مداخلات پیشگیرانه را مطرح می</span></span></span></span><span lang="AR-SA"><span b="" zar=""></span></span><span lang="FA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing: -0.1pt;">کند.</span></span></span></span><span lang="AR-SA"><span b="" zar=""><span style="color: black;"><span style="letter-spacing:-.2pt"></span></span></span></span></span></span></span><br>
</span></span></div>
<div><span style="font-size:12pt"><span style="line-height:150%"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt"><span style="line-height:150%"><span arial="" style="font-family:"><span style="letter-spacing:-.2pt"> </span></span></span></span></b></span><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt"><span style="line-height:150%"><span arial="" style="font-family:"><span style="letter-spacing:-.2pt">Background and purpose:</span></span></span></span></b> <span style="font-size:10.0pt"><span style="line-height:150%">Chemotherapy-induced peripheral neuropathy (CIPN) is a debilitating condition that may require reduction or discontinuation of chemotherapy. Identifying effective methods in treatment of established CIPN requires determining the frequency of CIPN. There is a lack of comprehensive studies on this issue, so, this study was conducted to investigate the frequency of peripheral neuropathy caused by chemotherapy in cancer patients in Sari Imam Khomeini Hospital.</span></span></span></span></span><br>
<span style="font-size:12pt"><span style="text-justify:kashida"><span style="text-kashida:0%"><span style="line-height:150%"><span style="text-autospace:none"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt"><span style="line-height:150%"><span arial="" style="font-family:">Materials and methods:</span></span></span></b><b> </b><span style="font-size:10.0pt"><span style="line-height:150%">This longitudinal study was done in cancer patients receiving thalidomide derivatives, vinca alkaloids, taxanes, proteasome inhibitors, platinums, and microtubule destabilizers in Comprehensive Cancer Center at Sari Imam Khomeini Hospital (2021-2022). Neurotoxicity was assessed by the EORTC QLQ-CIPN20 questionnaire before the start of the chemotherapy cycle and three months later. Data analysis was carried out in SPSS by applying Mann-Whitney U test, t-test, and Chi-square.</span></span></span></span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:150%"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt"><span style="line-height:150%"><span arial="" style="font-family:">Results:</span></span></span></b><b> </b><span style="font-size:10.0pt"><span style="line-height:150%">The study included 103 patients. Fifty-four patients (52.4%) were younger than 55 years old and 49 (47.6%) were older than 55 years of age. Forty-nine patients (47.6%) developed chemotherapy-induced neuropathy in the three-month follow-up. Symptoms were more frequent in women, but were not significant (P=0.11). The average body mass index in patients who experienced neuropathy was higher than that in patients without neuropathy.</span></span></span></span></span><br>
<span style="font-size:12pt"><span style="line-height:150%"><span style="vertical-align:top"><span new="" roman="" style="font-family:" times=""><b><span style="font-size:10.0pt"><span style="line-height:150%"><span arial="" style="font-family:">Conclusion:</span></span></span></b> <span style="font-size:10.0pt"><span style="line-height:150%">Almost half of the patients developed CIPN which raises the need for preventive training and interventions.</span></span></span></span></span></span><br>
</div>
سرطان, شیمی درمانی, نوروپاتی
cancer, chemotherapy, neuropathy
53
61
http://jmums.mazums.ac.ir/browse.php?a_code=A-10-1639-5&slc_lang=fa&sid=1
Ramin
Shekarriz
رامین
شکرریز
drraminshekarriz@yahoo.com